News
The ability to inhibit mitophagy converts fluorizoline into a promising antitumor agent
Fluorizoline was known for its pro-apoptotic action on various tumor cells. Now, a study by IDIBELL and the University of Barcelona shows that apart from promoting cell death, this compound inhibits the degradation of mitochondria.
Recognition of Dr. Mònica Povedano and the Functional Unit for Motor Neuron Disease work
Dr. Mònica Povedano, principal investigator at IDIBELL and head of the Functional Unit for Motor Neuron Disease at the Bellvitge University Hospital, has been awarded the 2020 Neuromuscular Disease Prize (scientific modality), granted by the Spanish Society of Neurology (SEN).
Cervical cytologies are not sensitive enough to detect endometrial cancer
The screening programs of cervical cancers diagnosticated by cervical cytologies have reduced the incidence and mortality of this cancer. However, a retrospective study of IDIBELL and ICO that included 371 women treated at the Hospital de Bellvitge has shown that these tests are not effective for endometrial cancer diagnosis.
IDIBELL participates in a study aimed to reduce the likelihood of liver failure in older transplant donors
MCJ protein silencing emerges as a new therapy to prevent liver failure after ischaemia-reperfusion in models of metabolic syndrome and ageing.
Identified a possible biomarker for the appearance of stones in cystinuria
A new study identified a possible biomarker for the appearance of cystine stones in the urinary tract in a murine model of cystinuria.
An indicator of endothelial dysfunction predicts the need for ICU transfer in patients with bone marrow transplantation
The hematology team, from IDIBELL and ICO, has published an article in the journal Blood Advances that proposes this index as a tool to identify patients with higher risk to be transferred to the Intensive Care Unit (ICU) after hematopoietic stem cell transplant.
A new drug increases the life expectancy of patients with very aggressive intraocular cancer
The results of a clinical trial, published in the New England Journal of Medicine, show that Tebentafusp is the first drug to increase overall survival in metastatic uveal melanoma, highly aggressive cancer that causes death in 50% of cases in less than a year.
COVID-19 patients undergoing emergency general and digestive surgery do not present more mortality
According to the study, the higher mortality should be attributed to the advanced aged and the worst preoperative health.
The excellence of human resources in research
IDIBELL’s strategic plan is closely linked to the human resources strategy for researchers. Here we present some of the concrete actions that we are carrying out in recruitment and selection, working conditions, ethical and professional aspects, and training and development.